NRG GU008 (INNOVATE)

Randomized Phase III Trial Incorporating Abiraterone Acetate with Prednisone and Apalutamide and Advanced Imaging into Salvage Treatment for Patients with Node-Positive Prostate Cancer After Radical Prostatectomy (Innovate*) - INtensifying treatment for NOde positive prostate cancer by VArying the hormonal ThErapy

Objective

This phase III trial studies how well adding apalutamide, abiraterone acetate, and prednisone to the usual hormone therapy and radiation therapy works compared to the usual hormone therapy and radiation therapy in treating patients with node-positive prostate cancer after surgery.

NCT#04134260

Clinical Trial Categories

• Prostate Cancer

Contact

NH Oncology Hematology Clinical Research Dept. at (603) 224-2556